The TB CAB publishes statements to proactively share its positioning on key issues before the TB field and in reaction to advances, news, and announcements made by other key stakeholders. Here are official statements from the TB CAB.
Global Tuberculosis Community Advisory Board (TB CAB) Announces New Website and New Members
3 September 2024
Statement from TAG, Global TB CAB on H56:IC31 Phase IIb trial results
21 December 2023
Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health
16 November 2022
TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction
14 July 2020
Research, Regulatory, and Access Considerations Regarding Pretomanid
18 May 2019
TB CAB Statement on Safety of Using Bedaquiline and Delamanid Together
12 March 2019
The TB CAB and TAG Welcome WHO Recommendation of Injectable-Free Regimens for the Treatment of RR/MDR-TB
17 August 2018
Global TB CAB Responds to New Bedaquiline Price
24 July 2018
South Africa Makes Bedaquiline Part of its Standard Recommended Treatment Regimen for Rifampicin-Resistant TB
19 June 2018